ARCHIVES

Patient Harm—Including One Death—Cited As Faculty Challenges MD Anderson Leadership

This article is from The Cancer Letter archive.

Vol. 39 No. 35 | September 20, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

HEW To Pay All Care Cost At 26 Hospices

January 11, 1980

Van Etten To Take Over As Director Of UC Irvine Chao Cancer Center

July 25, 2013

Gore Proposes New War On cancer, Double research Funding Over 5 years

July 9, 1999

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

August 31, 2012

In Brief: Weissman Heads DCBD Board; Extra Money For Grants Lifts Funding Level To 35%

October 14, 1977